The trial demonstrated that AUBAGIO could reduce the annualized relapse rate and prevent the progression of disability in patients with relapsing forms of multiple sclerosis (MS).
The study also revealed that the patients treated with AUBAGIO were comparatively relapse-free than with placebo, claimed the company.
TOWER is a randomized, double-blind phase III trial that enrolled 1,169 patients with relapsing MS across 26 countries and compared 7mg or 14mg once-daily, oral AUBAGIO against placebo.
Genzyme president and CEO David Meeker said both Phase III trials of AUBAGIO have impacted the progression of disability, making it the first and only oral MS therapy to do so.
"The convenience of a once daily oral therapy offers a meaningful alternative for patients wanting to avoid the burden of regular injections," Meeker added.